Abstract:Paradoxically, tumor development and progression can be inhibited and promoted by the immune system. After three stages of immune editing, namely, elimination, homeostasis and escape, tumor cells are no longer restricted by immune surveillance and thus develop into clinical tumors. The mechanisms of immune escape include abnormalities in antitumor-associated immune cells, selection for immune resistance to tumor cells, impaired transport of T cells, and the formation of an immunosuppressive tumor microenvironment. A population of distinct immature myeloid cells, myeloid-derived suppressor cells (MDSCs), mediate immune escape primarily by exerting immunosuppressive effects and participating in the constitution of an immunosuppressive microtumor environment. Clinical trials have found that the levels of MDSCs in the peripheral blood of cancer patients are strongly correlated with tumor stage, metastasis and prognosis. Moreover, animal experiments have confirmed that elimination of MDSCs inhibits tumor growth and metastasis to some extent. Therefore, MDSCs may become the target of immunotherapy for many cancers, and eliminating MDSCs can help improve the response rate to cancer treatment and patient survival. However, a clear definition of MDSCs and the specific mechanism involved in immune escape are lacking. In this paper, we review the role of the MDSCs population in tumor development and the mechanisms involved in immune escape in different tumor contexts. In addition, we discuss the use of these cells as targets for tumor immunotherapy. This review not only contributes to a systematic and comprehensive understanding of the essential role of MDSCs in immune system reactions against tumors but also provides information to guide the development of cancer therapies targeting MDSCs.

Disturbance of Differentiation and Maturation of Dendritic Cells and Tumor Escape

Tumor Cells Evade Immunosurveillance by Suppressing Dendritic Cell Function

Dysfunction of dendritic cells in tumor microenvironment and immunotherapy

Tumor-derived factors impaired motility and immune functions of dendritic cells through derangement of biophysical characteristics and reorganization of cytoskeleton.

Suppressive Mechanisms of Tumor Associated Immunosuppressive Cells in Immune Escape

Impaired function of dendritic cells within the tumor microenvironment

Advances in tumor-associated immunosuppressive cells and mechanism of immune escape

Research advance in Tumor-associated dendritic cells,macrophages,and myeloid derived suppressive cells

Suppressive Myeloid Cells Shape the Tumor Immune Microenvironment

Effect of Tumor Derived Factors on Tumor Associated Immnnosuppressive Cells

Myeloid-derived Suppressor Cells: Connection Between Inflammation and Cancer

Tumor microenvironment-related dendritic cell deficiency: a target to enhance tumor immunotherapy

Ovarian Carcinoma Cells Effectively Inhibit Differentiation and Maturation of Dendritic Cells Derived from Hematopoietic Progenitor Cells in Vitro

Dendritic cells dysfunction in tumor-draining lymph nodes

Tumor-Educated Tolerogenic Dendritic Cells Induce Cd3 Epsilon Down-Regulation and Apoptosis of T Cells Through Oxygen-Dependent Pathways

Relationship of Dendritic Cells and Tumor Immunity

Dendritic Cell Maturation in the Tumor Microenvironment

Dysfunction of Murine Dendritic Cells Induced by Incubation with Tumor Cells.

Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion

Biophysical heterogeneity of myeloid-derived microenvironment to regulate resistance to cancer immunotherapy

Dysfunction of Dendritic Cells in Tumor-Draining Lymph Nodes